Hypertrophic cardiomyopathy (HOCM) often goes unnoticed, yet as awareness grows, patients may find themselves more symptomatic than expected. How do doctors and patients navigate the array of management options, from medications to minimally invasive procedures or open-heart surgery? Discover what options offer the best chance for patients to feel their best, or even achieve a sense of normalcy, with minimal risk and hassle.

In this interview, Srihari S. Naidu, MD, FACC and Cindy L. Grines, MD, FACC, discuss HOCM: Selecting the Right Meds and Procedures.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Premature ventricular contractions (PVCs), commonly experienced as palpitations from occasional skipped heartbeats, are typically benign but can escalate to severe symptoms or heart failure in individuals with a high PVC burden. Understanding the most effective diagnostic tests for quantifying PVCs is crucial for guiding appropriate management strategies.

In this interview, Jim Cheung MD, FACC and Anthony N. DeMaria MD, MACC discuss PVC burden and its temporal variability.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Individuals from lower socioeconomic status (SES) backgrounds face heightened risks of morbidity and mortality, particularly in the context of health conditions such as cardiovascular disease. Despite this increased vulnerability, they often face barriers to accessing crucial secondary prevention programs, such as cardiac rehabilitation. How can we bridge this gap and ensure that these vulnerable patients receive the support they urgently need?

In this interview, Diann Gaalema, PhD and Anthony N. DeMaria, MD, MACC discuss financial incentives to improving cardiac rehab participation.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

In this interview, Stephen Greene, MD, FACC and Sidney C. Smith Jr., MD, MACC discuss inpatient initiation of HF GDMT.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Why should we assess plaque burden beyond luminal narrowing for cardiac prevention?

In this interview, Andrew Choi, MD, FACC and Clyde W. Yancy, MD, MSc, MACC discuss insights from data and studies involving plaque burden, morphology and flow.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

The most common congenital heart defect, congenital BAV, affects 1% of the population (2% in men, 0.5% in women), with a male-to-female ratio of 2:1 to 3:1. It's characterized by diverse phenotypic expressions and outcomes, falling into two prognostic groups:

1. Typical valvulo-aortopathy: Most common, with progressive BAV dysfunction and/or aorta dilatation but long-term survival similar to the general population.

1. Complex valvulo-aortopathy: Associated with significant concomitant disorders and/or accelerated valvulo-aortopathy, leading to inferior long-term survival.

BAV is a lifelong clinical condition with a morbidity burden exceeding 80%. Common complications include progression to ≥ moderate AS or AR, native aortic valve surgery, aortic aneurysm, surgery for aortic aneurysm, surgery for coarctation of the aorta, infective endocarditis, and aortic dissection.

In this interview, Hector I. Michelena, MD, FACC and W. Douglas Weaver MD, MACC discuss the history of and complications associated with bicuspid valvuloaortopathy.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Discover how detection of coronary artery calcium can greatly enhance risk prediction and risk mitigation, making it a critical tool for clinicians aiming to personalize patient care and prevent future cardiac events.

In this interview, Michael D. Shapiro, DO, FACC and Roger S. Blumenthal MD, FACC explore CAC scoring and the role of calcium detection in tailoring patient care, personalized risk assessment, and the prevention of future cardiac events.

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

In this interview, Leslie Cho, MD, FACC, and Steven E. Nissen MD, MACC explore the nuances of estrogen and testosterone replacement: who benefits, when to consider it, and how long it should last.

Subscribe to ACCEL